Fresenius Kabi and Bayer Schering Pharma enter into a Research, Development and License Agreement
Fresenius Kabi Deutschland GmbH and Bayer Schering Pharma AG have signed a Research, Development and License Agreement regarding the use of Fresenius Kabi Deutschland GmbH’s HESylation® Technology in a limited field of use.
Under the agreement, Fresenius Kabi will license its proprietary HESylation® Technology to Bayer Schering Pharma. This technology platform is based on hydroxyethyl starch (“HES”) and allows the prolongation of the active half-life of proteins.
Fresenius Kabi will be responsible for providing the appropriate HES derivative to Bayer Schering Pharma. Under the agreement, Bayer Schering Pharma will oversee the development and commercialisation. Fresenius Kabi will receive up-front and milestone payments as well as royalties on sales for licensing of the HESylation® Technology.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Cyrenaic Pharmaceuticals Reports Improvement of Negative Symptoms and Cognition in Schizophrenia Patients Treated with CYR-101 - Data suggest the drug could address the most important unmet medical need in schizophrenia

Laboratorios CINFA - Huarte-Pamplona, Spain
